Development asset linked to Cipla Australia Pty in public FDA and regional records. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
pharma
Cipla Australia Pty
Cipla Australia Pty Ltd
Cipla Australia Pty drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
AU HQ
TGA registrant Type
Company details
- Status
- Public
- HQ
- AU
- Programs
- 0
- Drugs
- 6
- Patents
- 0
Cipla Australia Pty pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Cipla Australia Pty drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Cipla Australia Pty in public FDA and regional records. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
gefitinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
icatibant
Blood and blood forming organs (B06)Blood and blood forming organs (B06) compound in Cipla Australia Pty's portfolio. Mechanism: Bradykinin B2 receptor antagonist.
- Mechanism
- Bradykinin B2 receptor antagonist
-
Development asset linked to Cipla Australia Pty in public FDA and regional records. Mechanism: Muscarinic acetylcholine receptor M3 antagonist.
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
Development asset linked to Cipla Australia Pty in public FDA and regional records.